Yosprala - (81mg;325/40 mg, Tablet, Delayed Release)

Generic Name	Aspirin and Omeprazole	Innovator	Genus Life
Dosage	81mg;325/40 mg, Tablet, Delayed Release	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****	*** \ **	**** **, ****	********* ** **** ***	********* ********	** ***** **, ****.

Chronology Of Events